摘要
神经内分泌肿瘤(NEN)是1种起源于神经内分泌细胞的异质性肿瘤, 以生长抑素受体(SSTR)表达增高为特征, 其发病率逐年上升。近年来, 利用放射性核素标记生长抑素类似物并与SSTR结合, 进而发挥杀伤肿瘤细胞作用的肽受体放射性核素治疗(PRRT)发展迅速。对于转移性、不可手术切除的SSTR阳性的NEN, PRRT已成为1种系统、有效、安全的治疗选择。该文综述PRRT对NEN患者的治疗方法、治疗效果、毒性反应和处理措施等, 并结合近年来国内外的重要研究进展, 探讨PRRT的未来发展方向。
Neuroendocrine neoplasms(NEN)are heterogeneous tumors originating from neuroendocrine cells,characterized by over expression of somatostatin receptors(SSTR)on the cell surface,with an increasing incidence year by year.In recent years,the peptide receptor radionuclide therapy(PRRT),using radionuclide-labeled somatostatin analogues to combine with SSTR,is developing rapidly and has played an important role in the treatment of NEN.PRRT is considered as a systemic,effective and safe treatment option for metastatic or unresectable SSTR-positive NEN.This article summarizes the method,effectiveness,toxic effect,and treatment measures of PRRT for NEN patients.The future development of PRRT is also discussed in combination with the important advances in recent years.
作者
王浩
张伟
朱朝晖
Wang Hao;Zhang Wei;Zhu Zhaohui(Department of Nuclear Medicine,Sichuan Provincial Academy of Medical Sciences-Sichuan Provincial People′s Hospital(Affiliated Hospital of the University of Electronic Science and Technology),Chengdu 610072,China;Department of Nuclear Medicine,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Science,State Key Laboratory of Complex,Severe and Rare Diseases,Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine,Beijing 100730,China)
出处
《中华核医学与分子影像杂志》
CAS
CSCD
北大核心
2023年第11期695-700,共6页
Chinese Journal of Nuclear Medicine and Molecular Imaging
基金
国家自然科学基金(81960320, 82272046)
中央高水平医院临床科研专项项目(2022-PUMCH-C-004, 2022-PUMCH-D-002)
中国医学科学院临床与转化医学研究专项(2022-I2M-C&T-A-008)
中国医学科学院医学与健康科技创新工程(2022-I2M-2-002, 2021-I2M-1-016)
四川省自然科学基金(2023NSFSC0635)
四川省卫生健康委员会科技项目(23LCYJ023)。
关键词
神经内分泌瘤
受体
肽
有机金属化合物
发展趋势
Neuroendocrine tumors
Receptors,peptide
Organometallic compounds
Trends
